| Abstract | We evaluated the efficacy of the nonergot dopamine receptor agonist pramipexole in 16 patients with advanced Parkinson's disease and marked rest tremor during an "on" period. The patients were drawn from a larger placebo-controlled, double-blind, randomized trial, which was not originally designed to investigate the effect of pramipexole on tremor. Eleven patients received pramipexole. The first effects were seen with a pramipexole dose of 0.75 mg/d with a reduction of the tremor item A of Unified Parkinson's Disease Rating Scale (UPDRS III, "on" state) by 25% and of rigidity and akinesia by 22%. Under the highest dose, 4.5 mg/d, the tremor score was improved by 61% over baseline (p < 0.0056, Wilcoxon signed rank) and the sum of rigidity and akinesia items by 66% (p < 0.0038, Wilcoxon signed rank). Five patients received placebo and did not improve. Based on this sample of patients, the nonergot dopamine receptor agonist pramipexole appears to have a potent anti-rest tremor action while being effective against akinesia and rigidity. |
| Authors | G Künig, O Pogarell, J C Möller, M Delf, W H Oertel
(Affiliation: Department of Neurology, Ludwig-Maximilian-University, Munich, Germany.)
|
| Journal | Clinical neuropharmacology
(Clin Neuropharmacol)
1999 Sep-Oct
Vol. 22
Issue 5
Pg. 301-5
ISSN: 0362-5664 UNITED STATES |
| PMID | 10516884
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
| Chemical References |
- Antiparkinson Agents
- Benzothiazoles
- Dopamine Agonists
- Thiazoles
- pramipexol
|
| Topics |
- Aged
- Antiparkinson Agents
(therapeutic use)
- Benzothiazoles
- Dopamine Agonists
(therapeutic use)
- Humans
- Middle Aged
- Parkinson Disease
(drug therapy)
- Severity of Illness Index
- Thiazoles
(therapeutic use)
- Treatment Outcome
- Tremor
(drug therapy)
|
